On October 20, Rick visited with Clinical Investigator Nasser Shuriquie, M.D., at Al-Rashid Hospital to discuss our Jordanian MDMA/PTSD study. The protocol was approved by the Al Rashid Institutional Review Board (IRB) several days before the meeting and is being prepared for submission to the Jordanian FDA. Rick also met with Mona Abdulhamid Alnsour, Ph.D., co-therapist on the study who is married to Dr. Nasser, in yet another husband/wife co-therapist team. MAPS has hired the Antaea Medical Services LTD to monitor the Jordanian study. On October 21, Rick met in Amman with the primary monitor on the study Kamila Novak, the firm’s founder Mr. Roussos, and their consultant Dr. Mohammad Rawashdeh (former Director of the Jordanian FDA). They also discussed MAPS working with this firm on the monitoring of our Israeli study. On October 22, Rick’s last meeting in Amman was with two State Department officials, both physicians, working at the U.S. Embassy in Amman. The officials had previously visited Al-Rashid Hospital as part of their Crisis Response evaluation work. There they had been told about MAPS’ sponsorship of the MDMA/PTSD study and had expressed an interest in meeting Rick. The meeting got off to a great start when one of the officials recalled having been in contact with Rick about ten years prior. Rick had contacted the Center for the Treatment of Torture, in Minneapolis, Minnesota, to see if they would be interested in a grant to study MDMA-assisted psychotherapy for PTSD. The Embassy official worked at the Center at that time, but the Center wasn’t in a position to conduct a clinical study. Ten years later, the Embassy official expressed appreciation for Rick’s dedication to develop MDMA/PTSD research including the Jordanian study. The meeting concluded with a discussion about MAPS’ U.S. MDMA/PTSD study with veterans. The two officials acknowledged the need for new treatments for PTSD and were sympathetic with MAPS’ Jordanian MDMA/PTSD project and U.S. study with veterans.